Floyd Sallee

Summary

Affiliation: University of Cincinnati
Country: USA

Publications

  1. doi request reprint Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder
    A C Childress
    Center for Psychiatry and Behavioral Medicine, Inc, Las Vegas, Nevada, USA
    Drugs Today (Barc) 48:207-17. 2012
  2. ncbi request reprint A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders
    Floyd Sallee
    Department of Psychiatry, University of Cincinnati, Cincinnati, OH 45219, USA
    J Child Adolesc Psychopharmacol 23:308-19. 2013
  3. pmc Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder
    Floyd R Sallee
    Department of Psychiatry, University of Cincinnati, Cincinnati, OH 45219, USA
    J Child Adolesc Psychopharmacol 22:206-14. 2012
  4. ncbi request reprint Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents
    Floyd R Sallee
    Department of Psychiatry, College of Medicine, University of Cincinnati, OH, USA
    J Am Acad Child Adolesc Psychiatry 45:720-8. 2006
  5. doi request reprint Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD)
    Floyd R Sallee
    University of Cincinnati, Department of Psychiatry, OH 45219, USA
    Expert Opin Pharmacother 11:2549-56. 2010
  6. doi request reprint The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder
    Floyd R Sallee
    Department of Psychiatry, University of Cincinnati, 260 Stetson Street, Suite 3200, Cincinnati, OH 45219, USA
    Postgrad Med 122:78-87. 2010
  7. ncbi request reprint Adderall XR: long acting stimulant for single daily dosing
    Floyd R Sallee
    Department of Psychiatry, 231 Albert Sabin Way, Cincinnati, OH 45267 0559, USA
    Expert Rev Neurother 4:927-34. 2004
  8. doi request reprint Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder
    Floyd R Sallee
    Department of Psychiatry, University of Cincinnati, Cincinnati, Ohio 45219, USA
    J Child Adolesc Psychopharmacol 19:215-26. 2009
  9. doi request reprint Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial
    Floyd R Sallee
    Department of Psychiatry, University of Cincinnati, 231 Albert Sabin Way, ML 0559, Cincinnati, OH 45267, USA
    J Am Acad Child Adolesc Psychiatry 48:155-65. 2009
  10. ncbi request reprint Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission
    Floyd R Sallee
    Pharmacology Research Center, Children s Hospital Medical Center, USA
    J Am Acad Child Adolesc Psychiatry 42:902-7. 2003

Research Grants

  1. CLONIDINE IN ADHD
    Floyd Sallee; Fiscal Year: 2000
  2. Cortical Excitability: Phenotype and Biomarker in ADHD Therapy
    Floyd Sallee; Fiscal Year: 2009
  3. CLONIDINE IN ADHD
    Floyd Sallee; Fiscal Year: 2005
  4. ADHD Phenotype Network: Animal Model to Clinical Trial
    Floyd Sallee; Fiscal Year: 2004
  5. CLONIDINE IN ADHD
    Floyd Sallee; Fiscal Year: 2003
  6. CLONIDINE IN ADHD
    Floyd Sallee; Fiscal Year: 2004
  7. CLONIDINE IN ADHD
    Floyd Sallee; Fiscal Year: 2002
  8. Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)
    Floyd Sallee; Fiscal Year: 2002
  9. CLONIDINE IN ADHD
    Floyd Sallee; Fiscal Year: 2001
  10. Cortical Excitability: Phenotype and Biomarker in ADHD Therapy
    Floyd R Sallee; Fiscal Year: 2010

Detail Information

Publications29

  1. doi request reprint Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder
    A C Childress
    Center for Psychiatry and Behavioral Medicine, Inc, Las Vegas, Nevada, USA
    Drugs Today (Barc) 48:207-17. 2012
    ..This review will focus on clonidine used in conjunction with stimulants to optimize treatment of ADHD...
  2. ncbi request reprint A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders
    Floyd Sallee
    Department of Psychiatry, University of Cincinnati, Cincinnati, OH 45219, USA
    J Child Adolesc Psychopharmacol 23:308-19. 2013
    ....
  3. pmc Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder
    Floyd R Sallee
    Department of Psychiatry, University of Cincinnati, Cincinnati, OH 45219, USA
    J Child Adolesc Psychopharmacol 22:206-14. 2012
    ..This post-hoc analysis further examines the effects of GXR on hyperactivity-impulsivity and inattentiveness...
  4. ncbi request reprint Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents
    Floyd R Sallee
    Department of Psychiatry, College of Medicine, University of Cincinnati, OH, USA
    J Am Acad Child Adolesc Psychiatry 45:720-8. 2006
    ....
  5. doi request reprint Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD)
    Floyd R Sallee
    University of Cincinnati, Department of Psychiatry, OH 45219, USA
    Expert Opin Pharmacother 11:2549-56. 2010
    ..GXR is a 'first in class' α(2A)-adrenoceptor agonist reformulated to optimize efficacy. GXR enters a rapidly growing but crowded ADHD market as an alternative not only to psychostimulants but also to atomoxetine...
  6. doi request reprint The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder
    Floyd R Sallee
    Department of Psychiatry, University of Cincinnati, 260 Stetson Street, Suite 3200, Cincinnati, OH 45219, USA
    Postgrad Med 122:78-87. 2010
    ....
  7. ncbi request reprint Adderall XR: long acting stimulant for single daily dosing
    Floyd R Sallee
    Department of Psychiatry, 231 Albert Sabin Way, Cincinnati, OH 45267 0559, USA
    Expert Rev Neurother 4:927-34. 2004
    ..Relevant clinical trials and the newest data from meeting reports are also discussed...
  8. doi request reprint Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder
    Floyd R Sallee
    Department of Psychiatry, University of Cincinnati, Cincinnati, Ohio 45219, USA
    J Child Adolesc Psychopharmacol 19:215-26. 2009
    ..This 2-year open-label study was conducted to further assess the long-term safety and efficacy of GXR...
  9. doi request reprint Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial
    Floyd R Sallee
    Department of Psychiatry, University of Cincinnati, 231 Albert Sabin Way, ML 0559, Cincinnati, OH 45267, USA
    J Am Acad Child Adolesc Psychiatry 48:155-65. 2009
    ..This study compared the efficacy of guanfacine extended release (GXR), a selective alpha(2A)-adrenoceptor agonist, with placebo in children and adolescents with attention-deficit/hyperactivity disorder (ADHD)...
  10. ncbi request reprint Pharmacodynamics of ziprasidone in children and adolescents: impact on dopamine transmission
    Floyd R Sallee
    Pharmacology Research Center, Children s Hospital Medical Center, USA
    J Am Acad Child Adolesc Psychiatry 42:902-7. 2003
    ..It is also an agonist at 5-HT(1A), which has been shown in rats to increase dopamine in prefrontal cortex. The objective of this study was to probe the dopamine agonist and antagonist pharmacodynamic properties of ziprasidone in youth...
  11. doi request reprint Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial
    Daniel F Connor
    Department of Psychiatry, University of Connecticut School of Medicine, Farmington, Connecticut 06030 1410, USA
    CNS Drugs 24:755-68. 2010
    ..Wayne, PA, USA) in the treatment of oppositional symptoms in children aged 6-12 years with a diagnosis of attention-deficit hyperactivity disorder (ADHD) and the presence of oppositional symptoms...
  12. doi request reprint Low cerebrospinal fluid neuropeptide Y concentrations in posttraumatic stress disorder
    Renu Sah
    Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45237, USA
    Biol Psychiatry 66:705-7. 2009
    ..Posttraumatic stress disorder (PTSD) is a stress-related anxiety disorder. We hypothesized that central nervous system NPY is dysregulated in PTSD and sought to redress the absence of central NPY data in the disorder...
  13. ncbi request reprint Dopamine transporter genotype influences the physiological response to medication in ADHD
    Donald L Gilbert
    Division of Neurology Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229 3039, USA
    Brain 129:2038-46. 2006
    ..In conclusion, MPH and ATX have similar effects on SICI in children with ADHD. A genetic variation in DAT1, previously linked to ADHD risk and MPH behavioural responses, influences the neurophysiological effects of both MPH and ATX...
  14. ncbi request reprint Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex
    Donald L Gilbert
    Division of Neurology, Cincinnati Children s Hospital Medical Center, University of Cincinnati, OH 45229, USA
    Neuropsychopharmacology 31:442-9. 2006
    ..Cortical inhibition, shown previously to be abnormal in ADHD, may play a key role producing behavioral pathology...
  15. doi request reprint Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study
    Robert L Findling
    Child and Adolescent Psychiatry, University Hospitals Case Medical Center, 11100 Euclid Ave, Cleveland, OH, USA
    J Clin Psychopharmacol 28:441-6. 2008
    ..These data provided support for exploration of a 30-mg/d dose in child/adolescent schizophrenia and bipolar disorder...
  16. ncbi request reprint Attention-deficit hyperactivity disorder diagnosis and treatment. Separating myth from substance
    Drew H Barzman
    Department of Psychiatry, Cincinnati Children s Hospital Medical Center, USA
    J Leg Med 25:23-38. 2004
  17. ncbi request reprint Association of cortical disinhibition with tic, ADHD, and OCD severity in Tourette syndrome
    Donald L Gilbert
    Division of Neurology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Mov Disord 19:416-25. 2004
    ..53; P = 0.003) than with tic severity (r = 0.42; P = 0.02), suggesting that in TS, the association between SICI and ADHD symptoms may be more consistent or direct than the association between SICI and tics...
  18. ncbi request reprint Relevance of neuropeptide Y (NPY) in psychiatry
    Katherine Eaton
    Department of Psychiatry, University of Cincinnati Medical Center, Cincinnati, OH 45267, USA
    Curr Top Med Chem 7:1645-59. 2007
    ..Reports on cerebrospinal fluid (CSF) NPY in subjects with depression indicate a dysregulation of central NPY in this disorder, however, other conditions still need to be investigated...
  19. pmc Interaction of NPY compounds with the rat glucocorticoid-induced receptor (GIR) reveals similarity to the NPY-Y2 receptor
    Renu Sah
    Department of Psychiatry, University of Cincinnati Medical Center, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    Peptides 28:302-9. 2007
    ..Our data report, for the first time, an interaction of NPY ligands with rGIR expressed in vitro, and indicate similarities between GIR and the NPY-Y(2) receptor...
  20. doi request reprint Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis
    W Burleson Daviss
    University of Texas Health Science Center at San Antonio, TX, USA
    J Am Acad Child Adolesc Psychiatry 47:189-98. 2008
    ..To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD)...
  21. ncbi request reprint Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial
    Donald L Gilbert
    Department of Neurology, Cincinnati Children s Hospital Medical Center, Division of Developmental and Behavioral Sciences Children s Mercy Hospital, Kansas City, KS, USA
    J Am Acad Child Adolesc Psychiatry 43:206-14. 2004
    ..To compare the tic suppression, electrocardiogram (ECG) changes, weight gain, and side effect profiles of pimozide versus risperidone in children and adolescents with tic disorders...
  22. ncbi request reprint A pilot safety study of repetitive transcranial magnetic stimulation (rTMS) in Tourette's syndrome
    Jeong Ho Chae
    Brain Stimulation Laboratory, Psychiatry Department, Medical University of South Carolina, Charleston, South Carolina, USA
    Cogn Behav Neurol 17:109-17. 2004
    ..We administered repetitive transcranial magnetic stimulation over prefrontal cortex or motor cortex, with either fast or slow repetitive transcranial magnetic stimulation, to 8 Tourette's syndrome patients...
  23. ncbi request reprint Transcranial magnetic stimulation-evoked cortical inhibition: a consistent marker of attention-deficit/hyperactivity disorder scores in tourette syndrome
    Donald L Gilbert
    Division of Neurology, Cincinnati Children s Hospital Medical Center and University of Cincinnati, OH 45229 3039, USA
    Biol Psychiatry 57:1597-600. 2005
    ..We sought to validate this observation...
  24. ncbi request reprint Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder
    Lorrin M Koran
    Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, Stanford, CA 94305, USA
    J Clin Psychopharmacol 26:79-83. 2006
    ..Small studies have suggested that intravenous clomipramine (CMI) may be more effective and induce faster improvement in obsessive-compulsive disorder than do orally administered serotonin reuptake inhibitors...
  25. ncbi request reprint A community assessment, open-label study of the safety, tolerability, and effectiveness of mixed amphetamine salts extended release in school-age children with ADHD
    Paul J Ambrosini
    Drexel University College of Medicine, Philadelphia, PA 19124, USA
    Curr Med Res Opin 22:427-40. 2006
    ..To assess the safety, tolerability, and effectiveness of mixed amphetamine salts extended release (MAS XR) in school-age children with attention-deficit/hyperactivity disorder (ADHD) treated in a community practice setting...
  26. ncbi request reprint SET-C versus fluoxetine in the treatment of childhood social phobia
    Deborah C Beidel
    Department of Psychology, University of Central Florida, Orlando, FL32186, USA
    J Am Acad Child Adolesc Psychiatry 46:1622-32. 2007
    ..To determine the efficacy of fluoxetine, pill placebo, and Social Effectiveness Therapy for Children (SET-C) for children and adolescents with social phobia...
  27. doi request reprint Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes
    Donna R Palumbo
    University of Rochester, USA
    J Am Acad Child Adolesc Psychiatry 47:180-8. 2008
    ..To determine the efficacy and safety of clonidine, used alone or in combination with methylphenidate, in treating attention-deficit/hyperactivity disorder (ADHD)...
  28. ncbi request reprint A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder
    Robert L Findling
    University Hospitals Case Medical Center, Cleveland, Ohio 44106, USA
    J Clin Psychiatry 69:149-59. 2008
    ..To evaluate the efficacy and safety of methylphenidate transdermal system compared with placebo, using osmotic-release oral system (OROS) methylphenidate as a reference therapy...
  29. ncbi request reprint Pediatric drug research and mental illness
    Floyd R Sallee
    FDA Consum 37:40. 2003

Research Grants10

  1. CLONIDINE IN ADHD
    Floyd Sallee; Fiscal Year: 2000
    ..abstract_text> ..
  2. Cortical Excitability: Phenotype and Biomarker in ADHD Therapy
    Floyd Sallee; Fiscal Year: 2009
    ..This proposal will further characterize both the physiologic relevance of SICI for ADHD as well as its utility to predict response to ADHD treatments such as atomoxetine. ..
  3. CLONIDINE IN ADHD
    Floyd Sallee; Fiscal Year: 2005
    ..abstract_text> ..
  4. ADHD Phenotype Network: Animal Model to Clinical Trial
    Floyd Sallee; Fiscal Year: 2004
    ..abstract_text> ..
  5. CLONIDINE IN ADHD
    Floyd Sallee; Fiscal Year: 2003
    ..abstract_text> ..
  6. CLONIDINE IN ADHD
    Floyd Sallee; Fiscal Year: 2004
    ..abstract_text> ..
  7. CLONIDINE IN ADHD
    Floyd Sallee; Fiscal Year: 2002
    ..abstract_text> ..
  8. Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)
    Floyd Sallee; Fiscal Year: 2002
    ..abstract_text> ..
  9. CLONIDINE IN ADHD
    Floyd Sallee; Fiscal Year: 2001
    ..abstract_text> ..
  10. Cortical Excitability: Phenotype and Biomarker in ADHD Therapy
    Floyd R Sallee; Fiscal Year: 2010
    ..This proposal will further characterize both the physiologic relevance of SICI for ADHD as well as its utility to predict response to ADHD treatments such as atomoxetine. ..